جميع الدراسات
نشط غير مجندالمرحلة 3تدخلي

A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease

Fabry disease is a rare inherited condition where fatty substances build up inside the body's cells. Over time, this buildup can damage vital organs such as the kidneys and heart. This Phase 3 trial is testing an oral treatment called lucerastat to see how safe and easy to take it is over a longer period. Only adults who have already completed the earlier six-month study (ID-069A301) can take part. In the UK and Europe, people may stay on the study for up to eight years, or until the drug becomes officially available on the NHS. Throughout the trial, doctors will closely check each person's general health, blood, and kidney function. Some men may also have a special check to see if fat levels inside kidney cells have improved.

نظرة سريعة

الحالة
نشط غير مجند
المرحلة
المرحلة 3
الراعي
Idorsia Pharmaceuticals Ltd.
الهدف من التسجيل
107
ابدأ
18 Dec 2018
التاريخ المتوقع للانتهاء
01 نوفمبر 2029

ما هو موضوع هذه الدراسة؟

Fabry disease is a rare genetic condition caused by a missing or faulty enzyme. Without enough of this enzyme, a fatty substance called Gb3 builds up in cells across the body. Over time, this buildup can cause pain, skin changes, and serious long-term damage to the kidneys, heart, and nervous system. Current standard treatments often require regular hospital visits for intravenous drips (infusions).

Lucerastat is an experimental medicine taken by mouth as a pill. It works differently from infusion therapies by reducing the production of these fatty substances in the first place. This study is an extension study, meaning it is designed to follow people who have already tested the medicine in an earlier trial, to see how it performs over years rather than months.

Finding out if a treatment is safe and well-tolerated in the long run is crucial for lifelong conditions like Fabry disease. Researchers hope that an effective oral tablet could give patients a simpler, more convenient way to manage their condition and protect their organs from damage.

النقاط الرئيسية

  • Tests the long-term safety of an oral treatment for Fabry disease.
  • Only available to people who completed the previous six-month study.
  • Participants may receive the medicine for up to eight years in Europe.
  • Requires regular clinic visits for blood, urine, and organ health checks.
  • Participation is voluntary and you can leave at any time without affecting your NHS care.

من قد يكون مؤهلاً؟

This study is only open to adults aged 18 and over who have already taken part in and completed the initial six-month study of lucerastat (known as study ID-069A301). Because of this, people who have not been in that specific trial cannot join.

To be eligible, participants must be generally stable. Women who could become pregnant and fertile men must agree to follow strict contraception rules throughout the study, as the effects of the medicine on an unborn baby are not fully known. Women must also agree to regular urine pregnancy tests.

You cannot join if you are pregnant, planning a pregnancy, or breastfeeding. You will also be excluded if you developed severe medical problems during the previous trial, such as serious kidney failure, acute kidney damage, a stroke, or heart failure that required hospital treatment.

هل يمكن أن تناسبك هذه الدراسة؟

أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.

  1. عمري 18 عامًا أو أكثر.
  2. I have Fabry disease.
  3. I fully completed the six-month treatment in the earlier study (ID-069A301).
  4. I am not pregnant, breastfeeding, or planning a pregnancy.
  5. I am willing to follow strict contraception rules during the study.
  6. I did not experience severe heart, stroke, or kidney complications during the previous trial.
أجب عن كل سؤال لترى نتيجتك.

ماذا يتضمن المشاركة؟

Taking part involves taking lucerastat capsules by mouth every day at home. You will need to attend regular clinic appointments so the study team can monitor your health. These visits will include physical examinations, blood and urine tests, and monitoring of your heart and kidneys. In Europe, your participation may last for up to eight years (96 months), or until the medicine receives a licence and becomes available. Some male participants who have taken the medicine for at least two years may also be invited to take part in an extra sub-study, which involves a kidney biopsy (taking a tiny sample of kidney tissue) to look closely at fat buildup.

المخاطر والفوائد المحتملة

The main potential benefit is continuing to receive an oral treatment that may help control Fabry disease and prevent cell damage, with close medical supervision. However, there may be side effects from taking the drug long-term, some of which may not yet be known. Tests like kidney biopsies also carry small risks of bruising, bleeding, or discomfort. Taking part is completely voluntary. You are free to leave the trial at any point, and choosing to withdraw will never affect your standard NHS care or your relationship with your medical team.

المواقع (42)

  • University of Alabama at Birmingham - Nephrology Research Clinic
    الرمز البريدي المؤكد
    برمنغهام، الولايات المتحدة
  • جامعة كاليفورنيا إيرفين
    الرمز البريدي المؤكد
    إرفاين، الولايات المتحدة
  • مستشفى الأطفال UCSF Benioff في أوكلاند
    الرمز البريدي المؤكد
    أوكلاند، الولايات المتحدة
  • University of Florida Clinical and Translational Science Institute, UF Clinical Research Center
    الرمز البريدي المؤكد
    غينزفيل، الولايات المتحدة
  • Rush University Medical Center - Dept of Pediatrics
    الرمز البريدي المؤكد
    شيكاغو، الولايات المتحدة
  • University of Iowa Stead Family Children's Hospital - Division of Medical Genetics
    الرمز البريدي المؤكد
    مدينة آيوا، الولايات المتحدة
  • مستشفى ماساتشوستس العام
    الرمز البريدي المؤكد
    بوسطن، الولايات المتحدة
  • Infusion Associates
    الرمز البريدي المؤكد
    غراند رابيدز، الولايات المتحدة
  • University of Pennsylvania - Dept of Medicine
    الرمز البريدي المؤكد
    فيلادلفيا، الولايات المتحدة
  • Greenwood Genetics Center
    الرمز البريدي المؤكد
    غرينفيل، الولايات المتحدة
  • Renal Disease Research Institute LLC
    الرمز البريدي المؤكد
    دالاس، الولايات المتحدة
  • Baylore University Medical Center
    الرمز البريدي المؤكد
    دالاس، الولايات المتحدة

أسئلة شائعة

How is lucerastat taken?

Lucerastat is taken as a pill by mouth, rather than as an intravenous drip into a vein.

Can anyone with Fabry disease join this study?

No. This study is strictly an extension trial for adults who already completed the earlier six-month trial (study ID-069A301).

How long will the trial last?

In Europe, participants can take part for up to eight years (96 months), or until the drug becomes commercially available.

Will taking part cost me anything?

No. The trial medicine and all study-related health tests are provided free of charge, and travel expenses are usually covered.

What happens if I decide I want to stop taking part?

You can leave the trial at any time without giving a reason. Your doctors will simply switch you back to standard NHS care.

كيفية معرفة المزيد

تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.

نقاش

مناقشة المجتمع

مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.